John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.
Â
Brief Synopsis:
Â
In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.
Â
In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).